Case Report

Rhabdomyolysis in a patient taking nebivolol

Ye Jin Kim, Hae Ri Kim, Hong Jae Jeon, Hyun Jun Ju, Sarah Chung, Dae Eun Choi, Kang Wook Lee, Ki Ryang Na
Renal Division, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea

Abstract

β-Blockers such as propranolol and labetalol are known to induce toxic myopathy because of their partial β2 adrenoceptor agonistic effect. Nebivolol has the highest β1 receptor affinity among β blockers, and it has never been reported to induce rhabdomyolysis until now. We report a patient who developed rhabdomyolysis after changing medication to nebivolol. A 75-year-old woman was admitted to our hospital because of generalized weakness originating 2 weeks before visiting. Approximately 1 month before her admission, her medication was changed from carvedilol 12.5 mg to nebivolol 5 mg. Over this time span, she had no other lifestyle changes causing rhabdomyolysis. Her blood chemistry and whole body bone scan indicated rhabdomyolysis. We considered newly prescribed nebivolol as a causal agent. She was prescribed carvedilol 12.5 mg, which she was previously taking, instead of nebivolol. She was treated by hydration and urine alkalization. She had fully recovered and was discharged.

Introduction

There are various causes of rhabdomyolysis. Recently, many medicines and substances, including lipid-lowering drugs (fibrates and statins), alcohol, heroin, cocaine [1], diuretics, antibiotics, and antifungal agents [2], have been reported as causes of rhabdomyolysis.

Among antihypertensive agents, it has been reported that β blockers, such as propranolol [3], labetalol [4], pindolol [5,6], and xamoterol [6], can result in toxic myopathy, which induces muscle cramps, pain, and muscle enzyme elevation.

Nebivolol is a selective β1-blocker with a nitric oxide–potentiating vasodilatory effect in comparison with other β blockers [7]. Nebivolol has a direct stimulatory effect on endothelial nitric oxide synthase, which results in increased levels of local nitric oxide [8,9]. It has been reported that nebivolol has an antioxidant effect [7,10]. In addition, there has been no published report of nebivolol-induced rhabdomyolysis. Although it is thought to have a more favorable side effect profile compared to other β blockers [11], nebivolol can possibly induce rhabdomyolysis. We treated a patient who developed rhabdomyolysis induced by nebivolol.

Case report

A 75-year-old woman was admitted to our hospital because of generalized weakness. The patient had been suffering from generalized weakness and anorexia for 2 weeks and remotely experienced symptom onset 1 month earlier. She had pain on the right knee and right thigh but no respiratory or cardiovascular symptoms suggesting infectious disease such as cough, sputum, rhinorrhea, sore throat, or fever. She had no other lifestyle changes, including trauma history, severe
exercise, burn, or diet, except for her change in medication from carvedilol 12.5 mg to nebivolol 5 mg 1 month before her admission. She visited a private clinic, and her serum levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were elevated markedly. She was transferred to an emergency room for further evaluation.

Previously, she was diagnosed with hypertension 11 years ago and severe cardiovascular disease (3-vessel disease) treated with a coronary artery bypass graft 4 years ago. She had taken fluvastatin 80 mg, valsartan 80 mg, aspirin 100 mg, and carvedilol 12.5 mg daily for 4 years. One month before her admission, carvedilol was changed to nebivolol 5 mg daily. She did not have diabetes mellitus, chronic hepatic disorder, or chronic kidney disease. She was a housekeeper without a history of smoking, alcohol intake, or herbal medication.

On physical examination, the patient was obese (body mass index, 26.57 kg/m²). Initial blood pressure was 136/66 mmHg. The heart rate was 62 beats/min. The respiration rate was 20 breaths/min. Body temperature was 36.7°C. Her mental status was alert, and orientation was intact. She cannot stand up on her own strength because of generalized weakness and right knee pain. Muscle strength was decreased to Grade II on the right lower leg and Grade IV on the other extremities and trunk. No significant tender point was found. Her urine was a dark color when examined in the emergency room.

On the day of admission, her blood test disclosed the following: AST 1,091 IU/L, ALT 913 IU/L, blood urea nitrogen (BUN) 56.8 mg/dL, creatinine 1.3 mg/dL, lactate dehydrogenase (LDH) 6,541 IU/L, creatine kinase (CK) 37,399 IU/L, CK-MB 399.7 ng/mL, troponin I 0.15 ng/mL, erythrocyte sedimentation rate 54 mm/h, and C-reactive protein 1.0 mg/dL. The serum myoglobin level was higher than the upper measurable range (>3,000 ng/mL).

The levels of hemoglobin (13.3 g/dL), platelet (218,000/µL), white blood cells (8,700/µL), total bilirubin (0.7 mg/dL), alkaline phosphatase (106 IU/L), plasma sodium (141 mEq/L), potassium (5.0 mEq/L), chloride (108 mEq/L), phosphorus (4.8 mg/dL), and total calcium (9.4 mg/dL) remained in the normal range. An arterial blood gas analysis at this time revealed a pH of 7.37, PCO₂ 37 mmHg, PO₂ 87 mmHg, HCO₃ 21.4 mmol/L, and O₂ saturation 96%.

The patient had the hepatitis B surface antibody. The results of the test for a hepatitis B surface antigen, hepatitis C antibody, reverse transcriptase-polymerase chain reaction of hepatitis C RNA, human immunodeficiency virus antibody, and rapid plasma reagin were all negative. The test for hepatitis A was not performed in consideration of low incidence of hepatitis A in her age.

The urine was strongly positive (++) for blood in dipstick test, but only 3–5 hours postfertilization (HPF) red blood cells were present on microscopic examination. Other laboratory results include specific gravity 1.015, pH 5.5, protein (+), glucose (−), ketone (−), bilirubin (−), urobilinogen (trace), nitrite (−), many white blood cells, 2–3/HPF squamous epithelial cells.

There was no remarkable finding other than a simple cyst on the right kidney on an abdominal ultrasonogram and a cardiac echocardiogram. An electrocardiogram showed sinus rhythm with normal intervals.

Technetium-99m hydroxymethane diphosphonate bone scintigraphy showed increased tracer uptake in the abdominal wall, both thighs, both deltoid muscles, and the right teres muscles (Fig. 1).

**Figure 1. Tc-99m HDP bone scintigraphy.** An increased tracer uptake was shown in the abdominal wall, both thighs, both deltoid muscles, and right teres muscles.

HDP, hydroxymethane diphosphonate.
She was thought to have drug-induced rhabdomyolysis arising from newly prescribed nebivolol. Prescription of nebivolol was stopped and changed to carvedilol 12.5 mg/d again. She was admitted and treated by massive hydration and urine alkalization. Altogether, 2 L of 5% dextrose saline solution mixed with sodium bicarbonate (20 mEq/L) was administered. We decided to observe for pyuria.

On the next day, reduction was observed in levels of CK (30,430 IU/L), liver transaminases (AST 778 IU/L and ALT 749 IU/L), and LDH (5,137 IU/L). BUN (1.54 mg/dL) and creatinine (1.54 mg/dL) levels were slightly elevated. On the third admission day, BUN (50.3 mg/dL) and creatinine (1.10 mg/dL) also showed decreases (Fig. 2).

On the sixth day after admission, all the urinalysis results were normal: specific gravity 1.011, pH 5.0, protein (−), erythrocyte (−), 1–2/HPF red blood cells, and 0–1/HPF white blood cells.

On the 10th day after admission, the level of AST was decreased to 28 IU/L and ALT to 94 IU/L. On the 12th day after admission, her blood chemistry showed creatinine 0.8 mg/dL, with cardiovascular disorders include [12]. Many combinations of drugs recommended for patients with hypertension, angina, myocardial infarction, and heart failure [12]. Generally, nebivolol is thought to have a more favorable side effect profile than other β blockers. Van Bortel et al [11] demonstrated that tolerability between nebivolol and angiotensin-converting enzyme inhibitors was similar, but nebivolol had better tolerability than other β blockers, calcium channel antagonists, and the angiotensin II receptor antagonists, including losartan, by analyzing data from 8 studies comparing nebivolol with other antihypertensive drugs. In a meta-analysis of 10 trials comparing nebivolol with atenolol, bisoprolol, and metoprolol, nebivolol showed few adverse events and drug withdrawals while exhibiting similar efficacy [26].
Rhabdomyolysis occurred while taking nebivolol, whereas it did not occur while taking carvedilol in this patient. Although the mechanism responsible for nebivolol-induced rhabdomyolysis is unclear, there are several reported differences between nebivolol and carvedilol that are useful to estimate the possible causes.

Carvedilol is a comprehensive β blocker that blocks β₁, β₂, and α receptors in the heart [27]. β₁-selective β blockers upregulate β₁ receptor density and increase β₁ receptor sensitivity to adrenergic stimulation; this has not been seen with carvedilol [28].

Nebivolol has the highest β₁ receptor affinity among β blockers, and α-blocking properties, and agonistic activity on β₂ receptors [8]. It also has vasodilating properties attributed to its interaction with the L-arginine nitric oxide pathway, a property not shared by other β blockers [29]. That is the reason why nebivolol led to a greater reduction of diastolic blood pressure than carvedilol although they demonstrated similar efficacy on systolic blood pressure reduction [30]. Produced via 2-step oxidation of L-arginine, nitric oxide has potent antitherosclerotic properties and inhibitory effect on the proliferation of smooth muscle cells in high concentrations [8].

There is a possibility that rhabdomyolysis was induced by the agonistic activity on β₂ receptors of nebivolol. Sprague et al [31,32] demonstrated that carvedilol reverses hyperthermia and subsequent rhabdomyolysis induced by 3,4-methylenedioxy-methamphetamine (MDMA, ecstasy) in an animal model. MDMA-induced hyperthermia is commonly associated with skeletal muscle breakdown, rhabdomyolysis, and renal failure. The mechanism of MDMA-induced hyperthermia is considered to be a combination of the following: α-1 adrenoceptor activation resulting in thermogenesis and visceral vasoconstriction to divert blood to skeletal muscle, β₂ adrenoceptor activation resulting in skeletal muscle thermogenesis, and activation of the skeletal muscle thermogenic protein, uncoupling protein-3. Carvedilol blocks these receptors so that it attenuates MDMA-induced CK release.

As far as we know, this is the first published case of nebivolol-induced rhabdomyolysis. In previously reported cases of rhabdomyolysis, there is only one patient who was indicated to have been taking a combination of drugs including nebivolol. Medications other than nebivolol were thought to be the causative agent in these cases [33].

Our case report shows the possibility of myotoxicity with nebivolol. The patient had taken carvedilol as a β blocker for 56 months and fluvastatin for 32 months, but her symptom occurred about 2 weeks after changing medication from carvedilol to nebivolol. Furthermore, she had completely recovered after hydration and restoring her medication to carvedilol. Moreover, the patient remained free from other complications of drugs, such as myopathy, for 9 months through to her most recent follow-up. These sequential events are enough to arouse suspicion that nebivolol has a causal relationship with rhabdomyolysis.

The amount of creatinine elevation (up to 1.5 mg/dL) was mild although the level of CK (37,399 U/L), AST (1,091 IU/L), and ALT (913 IU/L) was highly elevated in this case. We were unable to analyze a clinical difference between this case and other case reports of β blocker—induced rhabdomyolysis in detail because of the small number of cases.

Looking back in the case of this patient, we should also consider the possibility that rhabdomyolysis was induced by the interaction of nebivolol and other previously administered drugs such as fluvastatin. Omar et al [34] found that statin drugs alone or in combination therapy can cause rhabdomyolysis. Wagner et al [35] conducted an in vitro study and reported that combination treatment with propranolol and statins causes additive muscle toxicity in a dose-dependent manner, but the cohort study conducted by Setoguchi et al [3] found no evidence of a synergistic effect between the use of propranolol and statins in causing myopathy.

The patient was admitted in February which was the flu season, so we should also consider the possibility of infection-induced rhabdomyolysis in addition to medication. The most common viral etiology of rhabdomyolysis is influenza virus, followed by human immunodeficiency virus, Coxsackie virus, and Epstein–Barr virus, and the most common bacterial organisms are Legionella species, followed by Francisella tularensis, Streptococcus species, and Salmonella species [36]. The patient did not present any symptoms or signs to suspect an infection such as fever, chills, sore throat, cough, sputum, rhinorrhea, diarrhea, or abdominal pain. Therefore it was considered that there was no need for additional tests to rule out other respiratory or gastrointestinal infection.

Her technetium-99m hydroxymethane diphosphonate bone scintigraphy showed increased tracer uptake not only in the weakened right thigh but also the muscles of the trunk, which had no remarkable symptom. Soft tissue uptake at bone scintigraphy can be found because of benign (myositis ossificans and tumor calcinosis) and malignant (osteogenic sarcomas and adenocarcinomas) calcification, inflammation (polymyositis and soft tissue infection), and increased physical exercise [37–40]. There was no extraosseous calcification on her chest X-ray examination and no leukocytosis, focal erythema, or tenderness suggesting inflammation. She recovered only with massive hydration without administration of antibiotics or immunosuppressants, and her muscle weakness has not occurred in the 17-month follow-up period. It is suspected that the cause of the increased tracer uptake in the trunk is the increased use of muscles of the trunk and upper extremity due to the weakness in the right leg or personal habits of the patient.

In summary, nebivolol, a third-generation β blocker, has been in the limelight as a relatively safe antihypertensive agent so far, but there is a possibility of it causing rhabdomyolysis when taken alone or in combination with other agents. Therefore, when a patient taking nebivolol is suspected to be affected by myopathy or rhabdomyolysis, nebivolol should be considered as a potential culprit and be discontinued if possible.

**Conflicts of interest**

All authors have no conflicts of interest to declare.

**References**

[1] Bosch X, Poch E, Grau JM: Rhabdomyolysis and acute kidney injury. *N Engl J Med* 361:62–72, 2009

[2] Vanholder R, Sever MS, Erek E, Lamire N: Rhabdomyolysis. *J Am Soc Nephrol* 11:1553–1561, 2000

[3] Setoguchi S, Higgins JM, Mogun H, Mootha VK, Avorn J: Propranolol and the risk of hospitalized myopathy: translating chemical genomics findings into population-level hypotheses. *Am Heart J* 159:428–433, 2010
[4] Willis JK, Tilton AH, Harkin JC, Boineau FG: Reversible myopathy due to labelatal. *Pediatr Neurol* 6:275–276, 1990

[5] Aihara M, Takahashi R, Ohtake T, Komori T, Nagashima T, Tanabe H: Pindolol-induced rhabdomyolysis in sarcoid myopathy. *Rinsho shinkeigaku* 30:103–106, 1990 [in Japanese]

[6] Tomlinson B, Cruickshank J, Hayes Y, Renondin J, Lui J, Graham B, Jones A, Lewis A, Prichard B: Selective beta-adrenoceptor partial agonist effects of pindolol and xamoterol on skeletal muscle assessed by plasma creatine kinase changes in healthy subjects. *Br J Clin Pharmacol* 30:665–672, 1990

[7] Van de Water A, Janssens W, Van Neuten J, Xhonneux R, De Cree J, Van Bortel LM, Fici F, Mascagni F: Effects of nebulized bronchodilator on exercise-induced increases in heart rate and systolic blood pressure. *Circ Cardiovasc Drugs Ther* 12:339–344, 1998

[8] Munzel T, Gori T: Nebivolol: the somewhat-different beta-adrenoreceptor antagonist. *Am J Cardiovasc Drugs* 8:35, 2008

[9] Van Nueten L, De Creë J: Nebivolol: comparison of the effects of d-nebulol, l-nebulol, l-nebulol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure. *Circ Cardiovasc Drugs Ther* 26:189–202, 2008

[10] Gupta S, Wright HM: Nebivolol: a highly selective beta 1-adrenergic antagonist. *Drug Saf* 22:441–444, 2000

[11] Van Bortel LM, Fici F, Mascagni F: Efficacy and tolerability of nebulol compared with other antihypertensive drugs: a meta-analysis. *Am J Cardiovasc Drugs* 5:35–44, 2005

[12] Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, European Committee for Practice Guidelines (CPG): European Guidelines on the management of hyperlipidemia (the SAFARI trial). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). *Eur Heart J* 33:1635–1701, 2012

[13] Maron DJ, Fazio S, Linton MF: Current perspectives on statins. *Circulation* 101:207–213, 2000

[14] Ucar M, Mjörndal T, Dahlqvist R: HMG-CoA reductase inhibitors and myotoxicity. *Drug Saf* 22:441–457, 2000

[15] Dirks AJ, Jones KM: Statin-induced apoptosis and skeletal myopathy. *Am J Physiol Cell Physiol* 291:C1208–C1212, 2006

[16] Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmasino J: Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). *Am J Cardiol* 95:462–468, 2005

[17] Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, Stolzenbach JC, Williams LA, Jones PH: Efficacy and safety of rosuvastatin and fenofibrate combination therapy versus sim- vastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia. *Am J Cardiovasc Drugs* 10:175–186, 2010

[18] O’Riordan MA, Williams CD, Baker SK, Phillips PS: Clinical perspectives of statin-induced rhabdomyolysis. *Am J Med* 119:400–409, 2006

[19] Alshkeikh-Ali AA, Muddakuri PV, Han H, Karas RH: Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. *J Am Coll Cardiol* 50:409–418, 2007

[20] de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E, Investigators: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. *JAMA* 292:1307–1316, 2004

[21] Pettei MJ, Levy J, Abramson S: Nonocclusive mesenteric ischemia associated with proprotein convertase subtilisin/kexin type 9 activation: implications regarding splanchic circulation. *Pediatr Gastroenterol Nutr* 10:544–547, 1990

[22] Rooney M, Massey KL, Jamal F, Rosin M, Thomson D, Johnson DH: Acebutolol overdose treated with hemodialysis and extracorporeal membrane oxygenation. *Clin Pharmacol* 36:760–763, 1996

[23] Schofield PM, Beath SV, Mant TG, Bhamra R: Recovery after severe expronelol overdose complicated by rhabdomyolysis. *Hum Toxicol* 4:57–60, 1985

[24] Lynch GS, Ryall JG: Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. *Physiol Rev* 88:729–767, 2008

[25] Palmer KN: Muscle cramp and oral salbutamol. BMJ 2:833, 1978

[26] Ambrosioni E, Borghi C: Tolerability of nebulol in head-to-head clinical trials versus other cardioselective beta-blockers in the treatment of hypertension. *High Blood Press Cardiovasc Prev* 12:27–35, 2005

[27] Niicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O’Keefe JH: Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebulol). *Am J Cardiol* 111:765–769, 2013

[28] Packer M, Antonopoulos GV, Berlin JA, Chittams J, Konstam MA, Udelson JE: Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. *Am Heart J* 141:899–907, 2001

[29] Cleophas T, van Ouwerkerk B, van der Meulen J: Nebivolol, a third generation novel beta-blocker, systematic review. *J Am Coll Cardiol* 1:101–113, 2003

[30] Marazzi G, Volterrani M, Caminiti G, Iaia L, Massaro R, Vitale C, Spotoso B, Mercuro G, Rosano G: Comparative long term effects of nebulol and carvedilol in hypertensive heart failure patients. *J Card Fail* 17:703–709, 2011

[31] Sprague JE, Brutcher RE, Mills EM, Caden D, Rusniak DE: Attenuation of 3,4-methylenedioxyamphetamine (MDMA, Ecstasy)-induced rhabdomyolysis with alpha1- plus beta3-adrenoceptor antagonists. *Br J Pharmacol* 142:667–670, 2004

[32] Sprague JE, Moze P, Caden D, Rusniak DE, Holmes C, Goldstein DS, Mills EM: Carvedilol reverses hyperthermia and attenuates rhabdomyolysis induced by 3,4-methylenedioxyamphetamine (MDMA, Ecstasy) in an animal model. *Circ Res* 93:1311–1316, 2005

[33] László A, Kalabay L, Nemicik J: Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: contradictions between the two main therapeutic pathways. *BMC Res Notes* 6:52, 2013

[34] Omar MA, Wilson JP, Cox TS: Rhabdomyolysis and HMG-CoA reductase inhibitors. *Ann Pharm* 35:1096–1107, 2001

[35] Wagner BK, Kitami T, Gilbert TJ, Peck D, Ramanathan A, Schreiber SL, Golub TR, Mootha VK: Large-scale chemical dissection of mitochondrial function. *Nat Biotechnol* 26:343–351, 2008

[36] Singh U, Scheld WM: Infectious etiologies of rhabdomyolysis: three case reports and review. *Clin Infect Dis* 22:642–649, 1996

[37] Peller PJ, Ho VB, Kranzfeld MJ: Extracorporeal Te-99m MDP uptake: The pathophysiologic approach. *Radiographics* 13:715–734, 1993

[38] Louafi L, Collier BD, Mohammed AM: Nonosseous abnormalities on bone scans. *J Nucl Med Technol* 31:149–153; quiz 154–156, 2003

[39] Niemir Z, Oleksa R, Czepczynski R, Sowinski J: Increased uptake of technetium-99m methylene diphosphonate in muscles in the course of polymyositis. *Nucl Med Rev Cent East Eur* 8:153–154, 2005

[40] Lafforgue P, Siles S, Daumen-Legré V, Acquaviva PC: An unexpected, benign cause of increased muscular uptake at bone scintigraphy. *Clin Exp Rheumatol* 12:309–311, 1994